The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Dec. 31, 2024 – Jan. 22, 2025 • New York, New York ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...